Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Update

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the target of a large decline in short interest in February. As of February 28th, there was short interest totalling 2,080,000 shares, a decline of 16.8% from the February 13th total of 2,500,000 shares. Approximately 17.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 522,500 shares, the days-to-cover ratio is presently 4.0 days.

Jasper Therapeutics Stock Performance

NASDAQ:JSPR traded down $0.43 during mid-day trading on Tuesday, reaching $5.22. The stock had a trading volume of 240,180 shares, compared to its average volume of 267,088. The firm has a 50 day moving average price of $6.14 and a two-hundred day moving average price of $15.68. The stock has a market capitalization of $78.41 million, a P/E ratio of -1.10 and a beta of 2.23. Jasper Therapeutics has a one year low of $4.55 and a one year high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Thursday, February 27th. The company reported ($1.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.35). Research analysts forecast that Jasper Therapeutics will post -4.47 earnings per share for the current year.

Institutional Trading of Jasper Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of JSPR. FMR LLC bought a new stake in Jasper Therapeutics in the third quarter valued at approximately $722,000. BNP Paribas Financial Markets raised its holdings in shares of Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after acquiring an additional 1,698 shares in the last quarter. MetLife Investment Management LLC raised its holdings in shares of Jasper Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after acquiring an additional 3,873 shares in the last quarter. Ally Bridge Group NY LLC raised its holdings in shares of Jasper Therapeutics by 82.7% during the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after acquiring an additional 180,852 shares in the last quarter. Finally, Verition Fund Management LLC bought a new position in shares of Jasper Therapeutics during the third quarter valued at approximately $477,000. Institutional investors own 79.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on JSPR shares. BMO Capital Markets started coverage on Jasper Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $63.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Jasper Therapeutics in a report on Tuesday, March 11th. UBS Group started coverage on Jasper Therapeutics in a report on Thursday, February 13th. They set a “buy” rating and a $38.00 price objective for the company. JMP Securities reissued a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a report on Monday, January 6th. Finally, Royal Bank of Canada cut their price objective on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a report on Thursday, January 9th. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $62.50.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.